ResearcherThe Netherlands Cancer InstituteNo recent work listed
Robin M.J.M. van Geel
Matched on ORCID iD 0000-0003-1880-8131; OpenAlex author ID A5018295447. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2020: 2 papers · 2021: 1 paper
Papers 3
- Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. Co-author DOI 10.1002/onco.13631↗
- Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. First author DOI 10.1007/s00280-020-04066-4↗
- Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung… Co-author DOI 10.1038/s41416-020-0776-z↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Emilie M.J. van Brummelen · 3 shared papers, 2020–2021 · strength 0.30
- Paper Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic… DOI 10.1002/onco.13631↗
- Paper Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic… DOI 10.1007/s00280-020-04066-4↗
- Paper Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-… DOI 10.1038/s41416-020-0776-z↗
- Sanne C.F.A. Huijberts · 3 shared papers, 2020–2021 · strength 0.30
- Paper Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic… DOI 10.1002/onco.13631↗
- Paper Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic… DOI 10.1007/s00280-020-04066-4↗
- Paper Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-… DOI 10.1038/s41416-020-0776-z↗
- Frans L. Opdam · 3 shared papers, 2020–2021 · strength 0.30
- Paper Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic… DOI 10.1002/onco.13631↗
- Paper Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic… DOI 10.1007/s00280-020-04066-4↗
- Paper Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-… DOI 10.1038/s41416-020-0776-z↗
- René Bernards · 3 shared papers, 2020–2021 · strength 0.30
- Paper Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic… DOI 10.1002/onco.13631↗
- Paper Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic… DOI 10.1007/s00280-020-04066-4↗
- Paper Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-… DOI 10.1038/s41416-020-0776-z↗
- Jan H.M. Schellens · 3 shared papers, 2020–2021 · strength 0.30
- Paper Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic… DOI 10.1002/onco.13631↗
- Paper Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic… DOI 10.1007/s00280-020-04066-4↗
- Paper Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-… DOI 10.1038/s41416-020-0776-z↗
- Ferry A.L.M. Eskens · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.